PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

KarXT Cuts PANSS Scores in Acute Schizophrenia Without Dopamine Blockade

★ Editor's PickKarXTxanomelinetrospiummuscarinic agonistschizophreniaantipsychoticphase 3 RCTEMERGENT-2PANSSpsychiatry Psychiatry / Psychopharmacology

Background Information

KarXT shows promise in reducing schizophrenia symptoms significantly.

KarXT is being evaluated as a new treatment for schizophrenia, potentially offering an alternative to current therapies. KarXT significantly lowered the Positive and Negative Syndrome Scale (PANSS) total score by 9.6 points compared to placebo (p<0.0001). As a CNS-focused study, it lacks direct applicability to gastroenterology or hepatology. It is potentially impactful for neuropharmacology. KarXT shows promise as a novel schizophrenia treatment with significant and clinically meaningful efficacy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Correll CU, Miller AC, Sawchak S, Kaul I, Paul SM, Brannan SK

Citation: Correll CU, Miller AC, Sawchak S, et al. Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial. CNS spectrums. 2023;28(2):220. doi:10.1017/S1092852923001360

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.